Timing is everything: Order of administration of 5-aza 2′ deoxycytidine, trichostatin A and tamoxifen changes estrogen receptor mRNA expression and cell sensitivity

Cancer Letters

Volumn 275, Issue 2, 2009, Pages 178-184

  Hostetter, Christine L ^a   Licata, Lauren A ^b   Keen, Judith Clancy ^a  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b Department of Anesthesiology   (United States)

Author keywords

5 aza 2 deoxycytidine; Epigenetic; Estrogen receptor; HuR; MDA MB 231; Tamoxifen; Trichostatin A

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ESTROGEN RECEPTOR; MESSENGER RNA; TAMOXIFEN; TRICHOSTATIN A;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; EPIGENETICS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AZACITIDINE; CELL LINE, TUMOR; DRUG ADMINISTRATION SCHEDULE; ESTROGEN RECEPTOR MODULATORS; HUMANS; HYDROXAMIC ACIDS; RECEPTORS, ESTROGEN; RNA, MESSENGER; TAMOXIFEN;

EID: 59349106138     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.10.005     Document Type: Article

References (23)

1. Clark G. Prognostic and predictive factors. In: Harris J.R. (Ed). Diseases of the Breast (2000), Lippincott Williams & Wilkins, Philadelphia pp. 489-514
2. Clark G., Osborne C., and McGuire W. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J. Clin. Oncol. 2 10 (1984) 1102-1109
3. Clarke R., Dickson R.B., and Lippman M.E. Hormonal aspects of breast cancer. Crit. Rev. Oncol. Hematol. 12 (1992) 1
4. Keen J.C., and Davidson N.E. The biology of breast carcinoma. Cancer 97 3 Suppl. (2003) 825-833
5. Cameron E.E., Bachman K.E., Myohanen S., Herman J.G., and Baylin S.B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21 1 (1999) 103-107
6. Yang X., Phillips D.L., Ferguson A.T., et al. Synergistic activation of functional estrogen receptor (ER)-a by DNA methyltransferase and histone deacetylase inhibition in human ER-a-negative breast cancer cells. Cancer Res. 61 (2001) 7025-7029
7. Yan L., Nass S.J., Smith D., et al. Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor a (ER) in ER-negative human breast cancer cell lines. Cancer Biol. Ther. 2 5 (2003) 552-556
8. Issa J.-P.J., Zehnbauer B.A., Civin C.I., et al. The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. Cancer Res. 56 5 (1996) 973-977
9. Lapidus R.G., Nass S.J., and Davidson N.E. The loss of estrogen and progesterone receptor gene expression in human breast cancer. J. Mammary Gland Biol. Neoplasia 3 1 (1998) 85-94
10. Lapidus R., Ferguson A.T., Ottaviano Y., et al. Methylation of estrogen and progesterone receptor 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin. Cancer Res. 2 5 (1996) 805-810
11. Ottaviano Y., Issa J., Parl F., et al. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. 54 (1994) 2552-2555
12. Yang X., Blum J., Phillips D.L., Herman J.G., and Davidson N.E. Methylation-mediated hypoacetylation of histones H3 and H4 is associated with silencing of estrogen receptor-alpha (ER) in human ER-negative breast cancer cells. Proc. Am. Assoc. Cancer Res. 43 (2002) 163
13. Yang X., Ferguson A.T., Nass S.J., et al. Transcriptional activation of estrogen receptor a in human breast cancer cells by histone deacetylase inhibition. Cancer Res. 60 24 (2000) 6890-6894
14. Ferguson A.T., Lapidus R., Baylin S., and Davidson N.E. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res. 55 (1995) 2279-2283
15. Sharma D., Saxena N.K., Davidson N.E., and Vertino P.M. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res. 66 12 (2006) 6370-6378 10.1158/0008-5472.CAN-06-0402
16. Hostetter C., Licata L.A., Witkiewicz A., et al. Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells. Cancer Biol. Ther. 7 9 (2008)
17. Pryzbylkowski P., Obajimi O., and Keen J. Trichostatin A and 5 Aza-2′ deoxycytidine decrease estrogen receptor mRNA stability in ER positive MCF7 cells through modulation of HuR. Breast Cancer Res. Treat. (2007)
18. Brennan C.M., and Steitz J.A. HuR and mRNA stability. Cell. Mol. Life Sci. 58 2 (2001) 266-277
19. Pryzbylkowski P., Obajimi O., and Keen J. Trichostatin A and 5 Aza-2′ deoxycytidine decrease estrogen receptor mRNA stability in ER positive MCF7 cells through modulation of HuR. Breast Cancer Res. Treat. 111 (2008) 15-25
20. Keen J.C., Yan L., Mack K.M., et al. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor a (ER) in ER negative human breast cancer cells in combination with 5-aza 2′deoxycytidine. Breast Cancer Res. Treat. 81 3 (2003) 177-186
21. Keen J.C., Sholl L., Wills-Karp M., and Georas S.N. Preferential activation of nuclear factor of activated T cells c correlates with mouse strain susceptibility to allergic responses and Interleukin-4 gene expression. Am. J. Respir. Cell Mol. Biol. 24 1 (2001) 58-65
22. Abukhdeir A., Blair B., Brenner K., et al. Physiologic estrogen receptor alpha signaling in non-tumorigenic human mammary epithelial cells. Breast Cancer Res. Treat. 99 (2006) 23-33
23. Wang W., Fan J., Yang X., et al. AMP-Activated kinase regulates cytoplasmic HuR. Mol. Cell. Biol. 22 (2002) 3425-3426